Skip to main content
OpenTrials
Completed

NCT Number: NCT03421093

A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies

The study was designed to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

China PLA General Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

The trial is a multi-centre real-world non-interventional observational study to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors via a retrospectively review method on the study data on patient demographic/tumor biological characteristics and clinical treatments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >= 18 years old;
  • Pathologically diagnosed lung malignant tumors after surgeries;
  • Patients with lung surgeries;
  • Patients with complete medical health records and follow-up visit information (at least one follow-up visit);

Exclusion criteria

  • Patients who were not performed with surgeries;
  • Pathologically diagnosed patients with benign diseases after surgeries;

Treatment and study plan

Surgeries

Procedure

Surgeries or surgeries plus adjuvant therapies

Other names: Adjuvant therapies

Primary outcomes

  1. Demographic characteristics of the patients with lung malignant tumors who received surgeries

    Time frame: 2014 - 2017

    Demographic characteristics of the patients with lung malignant tumors who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery as measured by:

    • Age
    • Gender
    • Payment types
    • Insurance types
    • Smoking history
    • Complications and symptoms of complications
    • Respiratory functions
    • Type of diagnoses

Secondary outcomes

  1. Location of tumors and tumor sizes

    Time frame: 2014 - 2017

    Location of tumors and tumor sizes

  2. Tumor clinical/pathological staging

    Time frame: 2014 - 2017

    Tumor clinical/pathological staging

  3. Type of biomarkers

    Time frame: 2014 - 2017

    Type of biomarkers

Other outcomes

  1. Differences in overall survivals of the patients with surgeries

    Time frame: 2014 - 2017

    Differences in perioperative overall survivals and overall survivals of the patients who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery

  2. Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by tumor clinical/pathological staging

    Time frame: 2014 - 2017

    Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by tumor clinical/pathological staging

  3. Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by location of tumors and tumor sizes

    Time frame: 2014 - 2017

    Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by location of tumors and tumor sizes

  4. Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by duration and modes of surgeries

    Time frame: 2014 - 2017

    Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by duration and modes of surgeries

  5. Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by type of insurances

    Time frame: 2014 - 2017

    Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by type of insurances

  6. Overall survival in the patients with tumor size =< 2cm who received surgeries

    Time frame: 2014 - 2017

    Overall survival in the patients with tumor size =< 2cm who received surgeries

  7. Impact factors of patient survivals in the patients with N2 lung cancer with surgeries or surgeries plus adjuvant therapies

    Time frame: 2014 - 2017

    Impact factors of patient survivals in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies

  8. Overall survival in the patients with N2 lung cancer with surgeries or surgeries plus adjuvant therapies

    Time frame: 2014 - 2017

    Overall survival in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies

  9. Impact factors of patient survivals in the patients with small lung cancer with surgeries or surgeries plus adjuvant therapies

    Time frame: 2014 - 2017

    Impact factors of patient survivals in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies

  10. Overall survival in the patients with small lung cancer with surgeries or surgeries plus adjuvant therapies

    Time frame: 2014 - 2017

    Overall survival in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies

  11. Demographic characteristics of the patients with non-small cell lung cancer who were treated with chemotherapies, tyrosine kinase inhibitors, and other adjuvant therapies or were not treated with adjuvant therapies

    Time frame: 2014 - 2017

    Demographic characteristics of the patients with non-small cell lung cancer who were treated with chemotherapies, tyrosine kinase inhibitors, and other adjuvant therapies or were not treated with adjuvant therapies as measured by:

    • Age
    • Gender
    • Payment types
    • Insurance types
    • Smoking history
    • Complications and symptoms of complications
    • Respiratory functions
    • Type of diagnoses

  12. Tumor clinical/pathological types

    Time frame: 2014 - 2017

    Tumor clinical/pathological types

  13. Type of EGFR

    Time frame: 2014 - 2017

    Type of EGFR

  14. ECOG scores

    Time frame: 2014 - 2017

    ECOG scores

  15. 1-year and 3-year overall survivals

    Time frame: 2014 - 2017

    1-year and 3-year overall survivals

Sponsors and collaborators

Lead sponsor

West China Hospital

Other

Collaborators

  • LinkDoc Technology (Beijing) Co. Ltd.

Registry information

Official study title

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Clinical Characteristics of the Chinese Patients With Lung Malignant Tumors Who Received Surgeries or Surgeries Plus Adjuvant Therapies

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Feb 5, 2018
Registry last updated
May 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.